Drug Interactions
1.Concomitant use of this product with drugs that prolong the QT interval is prohibited (including but not limited to: clarithromycin, chloroquine, haloperidol, methadone, moxifloxacin, procainamide, amiodarone, pimozide).
2.As a phosphodiesterase 3 (PDE3) inhibitor, this product is prohibited from being used in combination with drugs with the same mechanism of action (such as cilostazol, amrinone, milrinone).
3.Concomitant use of this product with aspirin may increase the risk of bleeding, and such combination should be avoided as much as possible.
4.This product is mainly metabolized by CYP1A2. When used in combination with CYP1A2 inhibitors (fluvoxamine, ciprofloxacin), close monitoring is required, and the dosage should be adjusted according to the patient's response.
5.Omeprazole (a CYP1A2 inducer) may reduce the exposure of this product in the body, and it may be necessary to increase the dosage of this product.
6.This product slightly inhibits the activity of CYP1A2, which may lead to an increase in the plasma concentrations of drugs metabolized by this enzyme (theophylline, fluvoxamine, ondansetron).
Precautions
1.A daily dose of 1.5–3 mg is effective for most patients.
2.Monitor platelet count every 2 days during the first week of treatment and at least weekly before reaching the maintenance dose.
3.Liver function should be monitored regularly during treatment.
Contraindications and Precautions
1.This product is contraindicated in patients with hypersensitivity to anagrelide, and in patients with moderate to severe hepatic impairment.
2.Caution is advised in patients with cardiovascular disease and in those with mild hepatic impairment.
3.There are no adequate and well-controlled studies in pregnant women. This product should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
4.It is not known whether this product is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
5.This product is contraindicated in patients with Q-T interval prolongation.
6.This product may be used in patients for whom other treatment regimens (hydroxyurea, interferon) are contraindicated.
